Last Updated: November 16, 2026

Investigational Drug Information for Linifanib

« Back to Dashboard


What is the development status for investigational drug Linifanib?

Linifanib is an investigational drug.

There have been 12 clinical trials for Linifanib. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2010.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Hepatocellular, and Carcinoma. The leading clinical trial sponsors are Abbott, AbbVie, and Genentech, Inc.

Recent Clinical Trials for Linifanib
TitleSponsorPhase
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular CarcinomaSir Salimullah Medical College Mitford HospitalN/A
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the EndometriosisBioGene Pharmaceutical Ltd.Phase 1/Phase 2
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsAbbottPhase 1

See all Linifanib clinical trials

Clinical Trial Summary for Linifanib

Top disease conditions for Linifanib
Top clinical trial sponsors for Linifanib

See all Linifanib clinical trials

Linifanib Development Update and Market Projection

Last updated: September 4, 2026

Linifanib, also known as ABT-869, is an investigational oral multi-kinase inhibitor that targets VEGFR1-3, PDGFR, KIT, and related kinases. Abbott Laboratories, later AbbVie, discontinued its late-stage development after the drug failed to demonstrate the required benefit against sorafenib in advanced hepatocellular carcinoma. Linifanib has no FDA approval, no marketed formulation, no Orange Book listing, and no current commercial revenue.

The base-case market projection is therefore zero. A commercial revival would require a new sponsor, a new clinical strategy, and evidence of differentiation against approved oncology therapies, including immune checkpoint inhibitors and newer tyrosine kinase inhibitors.

What is the current development status of linifanib?

Linifanib is not an active late-stage development program. Its principal Phase III program in advanced hepatocellular carcinoma ended after failure to meet its efficacy objective.

Attribute Linifanib status
Generic name Linifanib
Development code ABT-869
Sponsor Abbott Laboratories, later AbbVie
Mechanism Oral VEGFR, PDGFR and KIT tyrosine kinase inhibitor
Lead indication Advanced hepatocellular carcinoma
Other investigated areas Renal cell carcinoma, colorectal cancer, breast cancer, acute myeloid leukemia and other solid tumors
FDA approval None
European approval None
Commercial launch None
Current development stage Inactive or discontinued
Current revenue $0
Orange Book listing None identified
Biosimilar status Not applicable

The pivotal HCC program was the FRONTIER trial, a randomized Phase III study comparing linifanib with sorafenib in patients with unresectable or metastatic HCC who had not received prior systemic therapy. The study did not establish linifanib as superior or acceptably noninferior to sorafenib on overall survival.

ClinicalTrials.gov continues to provide the principal public record for the FRONTIER study under NCT01009593.[1]

Why did linifanib fail in hepatocellular carcinoma?

Linifanib produced some disease-control and response activity, but the overall survival result did not support regulatory approval.

Reported results from the Phase III study included:

Endpoint Linifanib Sorafenib
Median overall survival Approximately 9.1 months Approximately 9.8 months
Overall response rate Approximately 13% Approximately 7%
Median progression-free survival Approximately 5.4 months Approximately 4.0 months
Overall survival hazard ratio Approximately 1.05 Comparator

The response and progression-free-survival signals did not offset the lack of overall-survival benefit. Linifanib also generated safety concerns typical of VEGF-pathway inhibitors, including hypertension, fatigue, hand-foot syndrome, proteinuria and other treatment-related toxicities.

The trial was conducted in a treatment environment dominated by sorafenib. The HCC treatment market has since shifted toward combination immunotherapy and newer systemic regimens. This makes the commercial and regulatory hurdle for reviving linifanib materially higher than it was during the original development period.

When did linifanib lose exclusivity?

Linifanib did not lose market exclusivity through generic entry because it never received marketing approval.

The relevant distinction is between patent protection and regulatory exclusivity:

  • Patent rights may have covered the compound, compositions, formulations or therapeutic uses.
  • FDA regulatory exclusivity was never granted because linifanib was not approved.
  • No reference listed drug was created.
  • No abbreviated new drug application pathway was established around a marketed linifanib product.
  • No commercial generic launch occurred.

Public FDA databases do not identify linifanib as an approved drug or an Orange Book-listed reference product.[2] Any remaining patent rights would not create a commercial monopoly without an approved product and an active development program.

What patents protect linifanib?

Linifanib was developed under Abbott intellectual property covering kinase-inhibitor compounds and related therapeutic uses. Public patent records associate ABT-869 with Abbott-originated patent families directed to substituted heterocyclic kinase inhibitors, pharmaceutical compositions and cancer treatment methods.

A precise commercial patent analysis is complicated by the absence of an approved product. There is no Orange Book patent listing that ties specific patents to an FDA-approved linifanib product. Patent categories relevant to the asset include:

Patent category Commercial relevance
Composition-of-matter patents Potential protection for linifanib and related analogues
Pharmaceutical-composition patents Potential protection for oral dosage forms and excipients
Method-of-use patents Potential protection for treating tumors or angiogenesis-related diseases
Combination-treatment patents Potential protection for use with chemotherapy or other anticancer agents
Manufacturing patents Potential protection for synthesis, intermediates or crystalline forms

The most important patent question for a revival would be whether any composition-of-matter or formulation claims remain enforceable in the target jurisdiction. Patent expiry alone would not resolve freedom-to-operate risk because manufacturing, polymorph, process and use claims can expire on different schedules.

No current Orange Book patent term extension or pediatric exclusivity applies to linifanib. The FDA Orange Book does not list an approved linifanib product.[2]

What was the FDA regulatory status of linifanib?

Linifanib did not receive FDA approval and has no approved indication, dosage, label, safety specification or commercial risk-management program.

The Phase III HCC failure prevented the program from progressing through a conventional new drug application review. The asset therefore has no:

  • FDA-approved indication
  • New Drug Application approval date
  • Prescription drug user fee action date
  • Orange Book reference product
  • Paragraph IV litigation history linked to an approved product
  • Hatch-Waxman exclusivity period
  • Pediatric exclusivity period
  • 505(b)(2) commercial precedent

Clinical development records show that linifanib was investigated in multiple oncology settings, but the absence of a successful registration package limited its regulatory value.[1]

Which companies are challenging linifanib?

No generic company is known to be challenging linifanib through a conventional Paragraph IV filing. That outcome is expected because Paragraph IV litigation requires an approved reference listed drug with Orange Book patents.

There is also no identified biosimilar challenge. Linifanib is a small molecule, not a biologic, so the relevant competitive pathway would be an abbreviated new drug application rather than a biosimilar application.

The practical competitive threats to a revived linifanib program would come from marketed or late-stage oncology products rather than from direct generic litigation.

Principal competitive products in hepatocellular carcinoma

Product or class Competitive position
Atezolizumab plus bevacizumab Established first-line immunotherapy and anti-VEGF combination
Durvalumab plus tremelimumab Established first-line immunotherapy combination
Sorafenib Original frontline kinase-inhibitor comparator
Lenvatinib Approved frontline multikinase inhibitor
Regorafenib Later-line option after sorafenib in selected patients
Cabozantinib Later-line multikinase inhibitor
Ramucirumab Biomarker-selected later-line option
Nivolumab and pembrolizumab Immunotherapy options in defined regulatory and clinical settings

A revived linifanib would need to show a clear advantage in response rate, overall survival, tolerability, biomarker selection, combination activity or treatment convenience.

What formulations are protected by linifanib patents?

Linifanib was developed as an oral small-molecule product. Public clinical development records describe oral administration, but there is no FDA-approved commercial formulation.

Potential formulation protection could include:

  • Immediate-release oral tablets or capsules
  • Solid pharmaceutical compositions containing linifanib
  • Particle-size or solubility-controlled formulations
  • Salt, crystalline or polymorphic forms
  • Manufacturing processes for active pharmaceutical ingredient production
  • Combination formulations with other anticancer agents

No approved label establishes a commercial dosage form, strength, administration schedule or formulation patent estate. That limits the value of any formulation rights because a sponsor would still need to reproduce the clinical and regulatory package.

What patent litigation affects linifanib?

No material public patent litigation involving an approved linifanib product has been established. There is no known Abbreviated New Drug Application dispute comparable to litigation involving marketed kinase inhibitors.

The absence of litigation does not mean that the asset has no patent history. It means the asset did not reach the commercial stage at which generic-entry litigation generally becomes significant.

Any future dispute would likely involve:

  1. Ownership or assignment of Abbott-originated patent families.
  2. Validity of composition-of-matter claims.
  3. Scope of method-of-treatment claims.
  4. Freedom to operate around manufacturing processes.
  5. Patent rights covering combinations with immunotherapies.
  6. Territorial differences in surviving claims.

How strong is the linifanib patent estate?

The patent estate has limited practical strength as a standalone commercial asset because clinical and regulatory failure has reduced its effective life.

Strengths

  • Linifanib was developed by a major pharmaceutical company with the resources to establish compound and process protection.
  • Composition-of-matter rights, if still enforceable in a particular jurisdiction, could create meaningful protection against direct copies.
  • The compound has a defined kinase profile and a documented clinical record.
  • Existing clinical data could reduce early development costs for a repurposing strategy.

Weaknesses

  • No approved product exists.
  • No regulatory exclusivity remains available from a prior approval.
  • The pivotal HCC efficacy result was negative.
  • The original commercial indication is crowded.
  • Broad VEGFR inhibition is associated with overlapping toxicity and limited differentiation.
  • Patent expiry and ownership would need to be verified family by family.
  • Existing trials may not satisfy current regulatory expectations for a new indication.

The estate is better characterized as a dormant development asset than as a protected commercial franchise.

What licensing deals involve linifanib?

No major publicly disclosed licensing transaction has established a current commercial partner for linifanib. The asset originated within Abbott’s pharmaceutical research organization and remained associated with Abbott or AbbVie during its clinical development.

There is no known active co-development, regional licensing, royalty-bearing commercialization or acquisition transaction supporting a current linifanib launch plan. A future transaction would likely be structured as an option or asset purchase rather than a conventional launch partnership because the program lacks an approved product and has a failed Phase III lead indication.

What is the market projection for linifanib?

The direct market projection is zero under the current status because linifanib is not approved, marketed or actively developed.

A scenario-based valuation is more useful than a conventional sales forecast:

Scenario Probability profile Commercial outcome
Base case: dormant asset Highest No sales; no new clinical investment
Repurposing in a biomarker-selected tumor Low Limited specialty-market opportunity
Combination development in HCC Low Potential niche launch if efficacy and safety improve
Broad HCC revival Very low Commercially difficult because of immunotherapy competition
Generic or follow-on launch Not applicable currently Requires an approved reference product or new approval

A successful revival could theoretically target the global liver-cancer market, but linifanib would not capture the market simply by returning to development. The drug would need to compete against established first-line immunotherapy combinations, approved kinase inhibitors and increasingly biomarker-defined treatment strategies.

Revenue exposure

Current revenue exposure is:

Revenue category Current estimate
Product sales $0
Royalty revenue No active public stream identified
Milestone revenue No active public program identified
Commercial manufacturing revenue $0
Risk-adjusted near-term revenue Effectively $0

A revived program could require several hundred million dollars in clinical, manufacturing and regulatory spending before commercialization. The failed Phase III outcome materially reduces the probability that such investment would produce an acceptable return.

What generic launch risks exist for linifanib?

There is no immediate generic launch risk because there is no approved linifanib product.

If a sponsor obtained approval in the future, generic risk would depend on:

  • Remaining composition-of-matter patent life
  • Scope of formulation claims
  • Patent protection for crystalline or polymorphic forms
  • Approved indications and method-of-use claims
  • Regulatory exclusivity attached to a new approval
  • The extent of clinical differentiation
  • Manufacturing complexity and active pharmaceutical ingredient availability

Linifanib is a small molecule and would generally be more exposed to conventional generic competition than a biologic. Manufacturing barriers could delay entry if synthesis requires difficult intermediates, proprietary processes or narrowly controlled solid-state forms, but those barriers would not substitute for enforceable patent or regulatory protection.

How does linifanib compare with sorafenib, lenvatinib and immunotherapy?

Factor Linifanib Sorafenib Lenvatinib Immunotherapy combinations
Approval status Unapproved Approved Approved Approved in defined settings
Development result in HCC Failed Phase III Established comparator Positive frontline development Current standard-setting class
Mechanism VEGFR, PDGFR, KIT inhibitor Multikinase inhibitor Multikinase inhibitor Immune checkpoint and anti-VEGF or CTLA-4 mechanisms
Commercial position None Mature Commercialized Strong current competitive position
Generic exposure No current product Increasing over time Patent and generic timing dependent Product-specific
Revival attractiveness Low Not applicable Not applicable Competitor class

Linifanib’s main potential advantage was activity across several angiogenic pathways. Its principal disadvantage was the absence of a survival advantage and the lack of a differentiated safety profile.

What is the outlook for linifanib development?

The most likely outcome is continued inactivity. A development restart would require one of the following strategic changes:

  • Biomarker selection based on angiogenic or kinase-dependence signatures
  • Combination with immunotherapy
  • A new indication with greater VEGFR or KIT dependence
  • Reformulation to improve exposure or reduce toxicity
  • Development in a tumor type where existing clinical signals are stronger
  • Use as a later-line treatment after immunotherapy failure

Even under these strategies, the program would face the need for new prospective clinical evidence. Historical response data alone would not support approval.

Key Takeaways

  • Linifanib, or ABT-869, is an unapproved investigational kinase inhibitor.
  • Abbott and AbbVie discontinued its lead HCC program after the Phase III FRONTIER study failed to establish an acceptable overall-survival result.
  • The drug has no FDA approval, Orange Book listing, regulatory exclusivity or commercial revenue.
  • No material Paragraph IV challenge, biosimilar dispute or generic launch applies.
  • The patent estate may include compound, formulation, use and manufacturing rights, but its current commercial value depends on jurisdiction-specific validity and remaining term.
  • HCC competition has intensified since linifanib development ended, particularly from atezolizumab-bevacizumab and durvalumab-tremelimumab.
  • The base-case revenue forecast is $0.
  • Any revival would be a high-risk repurposing program rather than a conventional late-stage asset.

FAQs

Is linifanib still being tested in clinical trials?

No active late-stage development program is publicly established. The principal HCC Phase III program was completed and did not support continued development.

Can linifanib be prescribed for liver cancer?

No. Linifanib has no FDA-approved indication and is not an approved prescription product.

Is linifanib a VEGFR inhibitor?

Yes. Linifanib is an oral multi-kinase inhibitor with activity against VEGFR1, VEGFR2, VEGFR3, PDGFR, KIT and related kinases.

Does linifanib have orphan-drug status?

No current FDA-approved orphan designation or commercial orphan-drug exclusivity is associated with linifanib.

Could linifanib be revived for combination therapy?

A revival is scientifically possible but commercially difficult. The most plausible strategy would involve biomarker-selected disease or combination treatment, but it would require new clinical evidence and face competition from approved immunotherapy-based regimens.

References

  1. ClinicalTrials.gov. (n.d.). Study of linifanib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: NCT01009593. U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT01009593

  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  3. ClinicalTrials.gov. (n.d.). Linifanib clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=linifanib

  4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

  5. Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, Z., Lin, X., & others. (2015). Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.